BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat

Reuters12-10

Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O:

SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION
SAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETIS

Source text: ID:nGNX1yxwPM

Further company coverage: SGMT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590058233?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590058233","market":"nz","top_or_hot":-1,"title":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat </title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Inc <span>SGMT.O</span>:</p><ul><li><p>SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION</p></li><li><p>SAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETIS</p></li></ul><p>Source text: <span>ID:nGNX1yxwPM</span></p><p>Further company coverage: <span>SGMT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat </title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences</a> Inc <span>SGMT.O</span>:</p><ul><li><p>SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION</p></li><li><p>SAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETIS</p></li></ul><p>Source text: <span>ID:nGNX1yxwPM</span></p><p>Further company coverage: <span>SGMT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:1","article_id":"2590058233","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590058233","pubTimestamp":1765370632,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SGMT":"Sagimet Biosciences Inc."},"translate_title":"简报-Sagimet的许可合作伙伴歌礼宣布接受Denifanstat的新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGMT":0.9},"content_text":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACCEPTANCE OF NEW DRUG APPLICATION FOR DENIFANSTAT FOR THE TREATMENT OF MODERATE TO SEVERE ACNE BY CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATIONSAGIMET BIOSCIENCES INC - GRANTS EXCLUSIVE LICENSE TO DENIFANSTAT FOR CHINA TO ASCLETISSource text: ID:nGNX1yxwPMFurther company coverage: SGMT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590058233","isCrawlerRequest":true}